THE LINSITINIB FDA APPROVAL DIARIES

The LIDS trial met its Principal endpoint with statistical importance with the 150mg BID dose. Linsitinib in this trial validated the safety profile witnessed in the prior oncology scientific studies and importantly demonstrated a good basic safety profile on vital adverse occasions (AEs) of curiosity for your IGF-1R focus on for example Listening